Biology Reference
In-Depth Information
Overall, the protein biomarker discovery and
development
12. Anderson NL. The clinical plasma proteome: a survey
of clinical assays for proteins in plasma and serum.
Clin Chem 2010;
-
cantly and become an important part of bio-
medical research aimed at detecting diseases at
early stages, reducing the
field is projected to grow signifi-
(2):177 e 85.
13. Li J, Kelm KB, Tezak Z. Regulatory perspective on
translating proteomic biomarkers to clinical diagnos-
tics. J Proteomics 2011;
56
financial burden on
healthcare and allowing for personalized medi-
cine approaches.
(12):2682 e 90.
14. Addona TA, Abbatiello SE, Schilling B, Skates SJ,
Mani DR, Bunk DM, et al. Multi-site assessment of the
precision and reproducibility of multiple reaction
monitoring-based measurements
74
of proteins
in
References
1. Legrain P, Aebersold R, Archakov A, Bairoch A,
Bala K, Beretta L, et al. The human proteome project:
current state and future direction. Mol Cell Proteomics
2011;
(7):633 e 41.
15. Prakash A, Rezai T, Krastins B, Sarracino D,
Athanas M, Russo P, et al. Platform for establishing
interlaboratory reproducibility of selected reaction
monitoring-based mass spectrometry peptide assays.
J Proteome Res 2010;
plasma. Nat Biotechnol 2009;
27
(7):M111.009993.
2. Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C,
Okamoto A, et al. Identi
10
(12):6678 e 88.
16. Lopez MF, Rezai T, Sarracino DA, Prakash A,
Krastins B, Athanas M, et al. Selected reaction
monitoring-mass spectrometric immunoassay respon-
sive to parathyroid hormone and related variants. Clin
Chem 2010;
9
cation by cDNA microarray
of genes involved in ovarian carcinogenesis. Cancer
Res 2000;
(18):5007 e 11.
3. Anastasi E, Marchei GG, Viggiani V, Gennarini G,
Frati L, Reale MG. HE4: a new potential early
biomarker for the recurrence of ovarian cancer.
Tumour Biol 2010;
60
56
(2):281 e 90.
17.
Issaq HJ, Xiao Z, Veenstra TD. Serum and plasma
proteomics. Chem Rev 2007;
(8):3601 e 20.
18. Anderson NL, Anderson NG. The human plasma
proteome: history, character, and diagnostic prospects.
Mol Cell Proteomics 2002;
107
(2):113 e 9.
4. Hartwell L, Mankoff D, Paulovich A, Ramsey S,
Swisher E. Cancer biomarkers: a systems approach.
Nat Biotechnol 2006;
31
(11):845 e 67.
19. Domon B, Aebersold R. Mass spectrometry and
protein analysis. Science 2006;
1
(8):905 e 8.
5. Wishart DS, Knox C, Guo AC, Eisner R, Young N,
Gautam B, et al. HMDB: a knowledgebase for the
human metabolome. Nucleic Acids Res 2009;
24
(5771):212 e 7.
20. Zhao X, Barber-Singh J, Shippy SA. MALDI-TOF MS
detection of dilute, volume-limitedpeptide sampleswith
physiological salt levels. Analyst 2004;
312
37
:
D603 e 10.
(9):817 e 22.
21. Sobhani K. Urine proteomic analysis: use of two-
dimensional
129
6.
Jensen ON. Modi
c proteomics: charac-
terization of post-translational modi
cation-speci
cations by mass
spectrometry. Curr Opin Chem Biol 2004;
gel
electrophoresis,
isotope
coded
(1):33 e 41.
7. LandegrenU, Vanelid J, HammondM, NongRY,WuD,
Ulleras E, et al. Opportunities for sensitive plasma
proteome analysis. Anal Chem 2012;
8
af
nity tags, and capillary electrophoresis. Methods
Mol Biol 2009;
:325 e 46.
22. Dudley JT, Butte AJ. Identi
641
cation of discriminating
biomarkers for human disease using integrative
network biology. Pac Symp Biocomput ; 2009:27 e 38.
23. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The
human urinary proteome contains more than 1500
proteins, including a large proportion of membrane
proteins. Genome Biol 2006;
84
(4):1824 e 30.
8.
Schroder C, Jacob A, Tonack S, Radon TP, Sill M,
Zucknick M, et al. Dual-color proteomic pro
ling of
complex samples with a microarray of 810 cancer-
related antibodies. Mol Cell Proteomics 2010;
9
(6):
1271 e 80.
9. Tabakman SM, Lau L, Robinson JT, Price J, Sherlock SP,
Wang H, et al. Plasmonic substrates for multiplexed
protein microarrays with femtomolar sensitivity and
broad dynamic range. Nat Commun 2011;
(9):R80.
24. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization
of urinary biomarkers to creatinine during changes in
glomerular
7
filtration rate. Kidney Int 2010;
78
(5):
:466.
10. Wu W, Slastad H, de la Rosa Carrillo D, Frey T,
Tjonnfjord G, Boretti E, et al. Antibody array analysis
with label-based detection and resolution of protein
size. Mol Cell Proteomics 2009;
2
486 e 94.
25. Yamamoto T. The 4th Human Kidney and Urine
Proteome Project (HKUPP) workshop. 26 September
2009, Toronto. Canada Proteomics 2010;
(11):2069 e 70.
26. Kuk C, Kulasingam V, Gunawardana CG, Smith CR,
Batruch I, Diamandis EP. Mining the ovarian cancer
ascites proteome
10
(2):245 e 57.
11. Picotti P, Aebersold R. Selected reaction monitoring-
based proteomics: work
8
ows, potential, pitfalls and
future directions. Nat Meth 2012;
for potential
ovarian cancer
9
(6):555 e 66.
biomarkers. Mol Cell Proteomics 2009;
8
(4):661 e 9.
Search WWH ::




Custom Search